Mitsubishi Tanabe Pharma
Mitsubishi Tanabe Pharma Corporation, often referred to as MTPC, is a prominent player in the global pharmaceutical industry, headquartered in Japan. Established in 1678, the company has evolved significantly, focusing on innovative drug development and therapeutic solutions primarily in the fields of neurology, immunology, and diabetes care. With a strong presence in Japan, North America, and Europe, Mitsubishi Tanabe Pharma is renowned for its unique core products, including treatments for multiple sclerosis and other chronic conditions. The company has achieved notable milestones, such as the successful launch of its flagship drug, which has positioned it as a leader in the biopharmaceutical market. Committed to advancing healthcare, Mitsubishi Tanabe Pharma continues to make significant contributions to patient well-being through its research and development initiatives.
DitchCarbon Score
How does Mitsubishi Tanabe Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Mitsubishi Tanabe Pharma's score of 55 is higher than 90% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Mitsubishi Tanabe Pharma's reported carbon emissions
In 2023, Mitsubishi Tanabe Pharma reported total greenhouse gas emissions of approximately 700,900,000 kg CO2e, with emissions distributed across various scopes: 18,700,000 kg CO2e (Scope 1), 36,300,000 kg CO2e (Scope 2), and 700,900,000 kg CO2e (Scope 3). The company has set ambitious climate commitments, aiming for a 45% reduction in Scope 1 and 2 emissions by 2030, compared to 2019 levels, and targeting net-zero emissions by 2050. In 2022, the total emissions were similar, with Scope 1 emissions at 20,300,000 kg CO2e and Scope 2 at 37,900,000 kg CO2e. The combined Scope 1 and 2 emissions for that year were about 62,900,000 kg CO2e. The company has consistently disclosed emissions data across all three scopes, demonstrating transparency in its sustainability efforts. Mitsubishi Tanabe Pharma's long-term strategy includes significant reductions in emissions from both direct operations and energy consumption, reflecting a commitment to environmental stewardship and alignment with global climate goals.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|
| Scope 1 | 35,400,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 71,800,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | 0,000,000 | 0,000,000 | 0,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Mitsubishi Tanabe Pharma is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
